Digest Network Come funziona
Network
/
Società
Ha
Non verificato

Harmony Biosciences Holdings, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteWeb e Social Network

30 comunicati stampa

Guarda tutti i comunicati
04/03/2026
Eventi
Salute
Medicina - Varie
Sanità
Farmaceutica
Biotecnologia
Harmony Biosciences to Participate in Upcoming Investor Conferences
Fonte
Harmony Biosciences Holdings, Inc.
Emittente
Business Wire
1.00
0
24/02/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Scienza
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Sanità
Harmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 Billion
Fonte
Harmony Biosciences Holdings, Inc.
Emittente
Business Wire
1.00
0
17/02/2026
Industria
Biotecnologia
Farmaceutica
Salute
Igiene alimentare
Famiglia
Infanzia
Vetrine/Shopping
Medicina - Varie
Harmony Biosciences Receives U.S. Food and Drug Administration Approval for WAKIX® (pitolisant) for the Treatment of Cataplexy in Pediatric Narcolepsy
Fonte
Harmony Biosciences Holdings, Inc.
Emittente
Business Wire
1.00
0
10/02/2026
Biotecnologia
Farmaceutica
Salute
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Harmony Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
Fonte
Harmony Biosciences Holdings, Inc.
Emittente
Business Wire
1.00
0
12/01/2026
Salute
Medicina - Varie
Sanità
Farmaceutica
Biotecnologia
Industria
Harmony Biosciences Guides to Over $1 Billion in WAKIX® Revenue in 2026; Advancing Robust Late-Stage Pipeline With Potential for Long-term Value Creation
Fonte
Harmony Biosciences Holdings, Inc.
Emittente
Business Wire
1.00
0
07/01/2026
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Web e Social Network
Eventi
Harmony Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
Fonte
Harmony Biosciences Holdings, Inc.
Emittente
Business Wire
1.00
0
08/12/2025
Industria
Scienza
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Harmony Biosciences Presents Clinically Meaningful Open-Label Extension Study Effectiveness Data for EPX-100 in Dravet Syndrome
Fonte
Harmony Biosciences Holdings, Inc.
Emittente
Business Wire
1.00
0
02/12/2025
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Industria
Harmony Biosciences to Present New Open-Label Extension Data from Phase 3 ARGUS Trial at the 2025 American Epilepsy Society Annual Meeting
Fonte
Harmony Biosciences Holdings, Inc.
Emittente
Business Wire
1.00
0
24/11/2025
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Industria
Harmony Biosciences Announces Positive Results From the Pivotal Bioequivalence Study for Pitolisant Gastro-Resistant Formulation
Fonte
Harmony Biosciences Holdings, Inc.
Emittente
Business Wire
1.00
0
19/11/2025
Eventi
Industria
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Harmony Biosciences Announces Initiation of First-In-Human Study With Potential Best-In-Class Orexin 2 Receptor Agonist (BP1.15205) for Central Disorders of Hypersomnolence
Fonte
Harmony Biosciences Holdings, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0